NIH Registers Phase 2 ICONIC Trial: Ivermectin + Immune Checkpoint Inhibitors for Cancer

Ivermectin, a well-known antiparasitic drug, has attracted growing attention from oncology researchers due to its preclinical activity against multiple cancer pathways, including Wnt/β-catenin, PI3K/AKT/mTOR, and immune modulation. Despite widespread off-label use—documented in a 2023 Ecuadorian survey where 19% of respondents reported using ivermectin as a cancer adjunct—controlled clinical evidence has remained virtually absent. A single partially reported study combining ivermectin with anti-PD-1 therapy in metastatic triple-negative breast cancer (TNBC) showed no treatment-related toxicities in the first nine patients, but full results have not been published.

On July 2026, the U.S. National Institutes of Health (NIH) registered a new clinical trial that may change this landscape. Named ICONIC (Ivermectin Combined With Immune Checkpoint Inhibition in Cancer), the trial is listed as a Phase 2 study with an estimated start date of September 2026 and is currently not yet recruiting. This development marks the first NIH-registered Phase 2 study specifically designed to evaluate ivermectin alongside modern immunotherapy in cancer patients. For those tracking ivermectin immunotherapy research, this trial is the most concrete clinical development to date.

Patients interested in ivermectin as part of their protocol should continue to consult with their oncologists and consider using a dosing calculator to understand how adjunct agents may fit within established frameworks. The ICONIC trial will not provide results for years, but its registration signals that the scientific community is taking ivermectin's anticancer potential seriously enough to invest in controlled human studies.

Table of Contents

• ICONIC Trial Design and Objectives
• Why This Matters for the Field
• How Ivermectin Might Synergize With Immunotherapy
• Frequently Asked Questions

ICONIC Trial Design and Objectives

According to the ClinicalTrials.gov listing (NCT07487805), the ICONIC trial has the following structure:

• Phase: Phase 2
• Condition: Solid Tumor, Adult
• Interventions: Intermediate-dose ivermectin and high-dose ivermectin, combined with immune checkpoint inhibitors
• Status: Not yet recruiting
• Estimated start date: September 2026

The trial will test two dose levels of ivermectin in combination with standard immune checkpoint blockade therapy. The primary objective is to evaluate whether ivermectin can enhance the efficacy of immunotherapy in adult solid tumor patients. Secondary objectives likely include safety profiling, pharmacokinetic monitoring, and exploratory biomarker analysis, though the full protocol details remain unpublished.

Why This Matters for the Field

The registration of the ICONIC trial is significant for several reasons:

• From anecdote to evidence: Until now, most human data on ivermectin in cancer have come from observational studies, case reports, and small cohorts. A Phase 2 randomized or controlled trial would provide the first rigorously collected efficacy signal.
• Combination with immunotherapy: Ivermectin's preclinical activity includes modulation of immune checkpoints, TGF-β signaling, and tumor microenvironment remodeling. Testing it alongside approved checkpoint inhibitors is a mechanistically rational design.
• NIH sponsorship: Federal registration adds credibility and ensures adherence to Good Clinical Practice standards, independent oversight, and public reporting of results.

For patients, the key message is one of cautious optimism. The trial exists, but recruitment has not begun, and results will not be available for several years. No one should alter their current treatment plan based on trial registration alone.

How Ivermectin Might Synergize With Immunotherapy

Preclinical research has proposed several mechanisms by which ivermectin could enhance immunotherapy:

• Immune checkpoint modulation: Ivermectin has been shown to inhibit the TGF-β pathway, which is a major driver of immunosuppression in the tumor microenvironment. By reducing TGF-β signaling, ivermectin may increase the responsiveness of "cold" tumors to checkpoint inhibitors.
• PD-L1 suppression: Some studies suggest ivermectin can downregulate PD-L1 expression on cancer cells, potentially reducing the adaptive immune resistance that limits checkpoint inhibitor efficacy.
• Autophagy induction: Ivermectin promotes autophagy in cancer cells, which can enhance antigen presentation and improve the immunogenicity of the tumor.

These mechanisms are supported by laboratory data but remain unproven in human cancers. The ICONIC trial is designed to test whether these preclinical observations translate into clinical benefit.

Frequently Asked Questions

Shop Sanare Lab

Lab-tested ivermectin for researchers exploring repurposed antiparasitic oncology.

Disclaimer: Links are informational and do not constitute medical advice. Always consult a healthcare provider before using any supplement or medication.

References

1. ClinicalTrials.gov NCT07487805: Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC). Registered July 2026. Status: Not yet recruiting. Phase 2.
2. ClinicalTrials.gov NCT05318469: Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer. Status: Recruiting.
3. Ivermectin and Cancer Immunotherapy: What the Research Shows — Sanare Lab long-read.
4. Ivermectin: What It Is, How It Works, and Why It's Used — Sanare Lab long-read.